The value of pharmaceutical merger and acquisitions declined considerably in 2002 as big pharma took a risk-averse approach to improving pipelines and sales.

The value of pharmaceutical merger and acquisitions declined considerably in 2002 as big pharma took a risk-averse approach to improving pipelines and sales.

Although Pfizer's roughly $60 acquisition of Pharmacia is one time again raising the bar for critical mass among the pharmaceutical majors, the view for pharmaceutical mergers and acquisitions (M&A) activity is subdu Pharmaceutical M&A reached a newly come low in deal values in 2002 as companies sought to take a more risk-averse approach to improving put drugs into output with a focus forward product-based acquisitions. Still,

...